Inter- and Intra-Rater Reliability of the Brief Psychiatric Rating Scale

Flemenbaum, Abraham; Zimmermann, Robert

doi:10.2466/pr0.1973.33.3.783

Cited by 117 publications

(61 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Motor outcome parameters were the "cumulative daily off time" recorded by patients' diaries and the UPDRS. Patients also underwent psychiatric assessments by means of the Beck Depression Inventory [11] (BDI), the Montgomery Asberg Depression Scale [12] (MADRS) and the Brief Psychiatric Rating Scale [13] (BPRS).…”

Section: Clinical Evaluation/data Analysis/statisticsmentioning

confidence: 99%

Negative impact of borderline global cognitive scores on quality of life after subthalamic nucleus stimulation in Parkinson's disease

Witt

Daniels

Krack

et al. 2011

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) significantly improves quality of life (QoL) inParkinson's disease (PD). Dementia is considered as a contraindication for STN-DBS. However, no controlled study assessed the impact of STN-DBS on the QoL and motor outcome in PD patients with a borderline global cognitive impairment. We studied clinical baseline and progression parameters in a cohort of STN-DBS patients with a global cognitive score still in the non-demented range but scoring in the lowest quartile of the Mattis Dementia Rating Scale (MDRS), a measure of global cognitive functioning. Data from a German randomised controlled study comparing DBS (60 patients) with best medical treatment (BMT, 59 patients) were analysed. Changes in patients' QoL scores were assessed using the Parkinson's disease questionnaire (PDQ-39) at baseline and at the 6 months follow up. Patients were split into four groups according to their MDRS performance at baseline and these groups were compared in the context of motor outcome and QoL. Twelve out of sixty patients of the STN-DBS group scored in the lowest quartile of the MDRS (range between one hundred thirty and one hundred thirty seven points). An individual analysis revealed that 3 of 12 patients showed a clinical relevant improvement in QoL whereas the group statistics did not reveal any significant improvement in QoL measures after STN-DBS compared to the BMT group. Since this failure to improve in QoL cannot be explained by a failure to improve in motor functions, stimulation settings and psychiatric scales after STN-DBS, the failure to improve in QoL in patients with a borderline global cognitive score might be specifically related to lower cognitive functioning.

show abstract

Section: Clinical Evaluation/data Analysis/statisticsmentioning

confidence: 99%

Negative impact of borderline global cognitive scores on quality of life after subthalamic nucleus stimulation in Parkinson's disease

Witt

Daniels

Krack

et al. 2011

Journal of the Neurological Sciences

View full text Add to dashboard Cite

show abstract

“…Anxiety was rated with the Beck anxiety inventory, 30 a self-rating assessment, with scores that range from 0 to 63 (high scores indicate more severe anxiety). The brief psychiatric rating scale 31 was used as a further psychiatric assessment of a wider range of symptoms, including psychosis (the total score of 18 clinician-rated items can range from 18 to 126, where high scores indicate poor mental health). Subscores of the brief psychiatric rating scale (anxiety and depression, anergia, thought disorders, activity, and hostility) were analysed separately.…”

Section: Dbsmentioning

confidence: 99%

Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study

Witt

Daniels

Reiff

et al. 2008

The Lancet Neurology

587

433

View full text Add to dashboard Cite

SummaryBackground Deep brain stimulation (DBS) of the subthalamic nucleus (STN) reduces motor symptoms in patients with Parkinson's disease (PD) and improves their quality of life; however, the eff ect of DBS on cognitive functions and its psychiatric side-eff ects are still controversial. To assess the neuropsychiatric consequences of DBS in patients with PD we did an ancillary protocol as part of a randomised study that compared DBS with the best medical treatment.

show abstract

“…16 Other measures of outcome employed were the Brief Psychiatric Rating Scale (BPRS) 17 and the Schedule for the Assessment of Negative Symptoms (SANS). 18 Side effects were evaluated by the Simpson-Angus Scale for Extrapyramidal Symptoms (SAS), 19 the Barnes Akathisia Scale (BAS) 20 and the Abnormal Involuntary Movement Scale (AIMS).…”

Section: Efficacy and Safety Evaluationsmentioning

confidence: 99%

No influence of FAT polymorphisms in response to aripiprazole

et al. 2009

View full text Add to dashboard Cite

The aim of this study was to investigate possible influences of a set of markers in the FAT gene (rs2306987, rs2306990, rs2637777 and rs2304865) on efficacy and tolerability of aripiprazole in the treatment of schizophrenic patients. Efficacy was assessed at baseline and weeks 1, 2, 4, 6, 8 and 12 using the Clinical Global Impression Severity and Improvement scale (CGI-S; CGI-I), the Brief Psychiatric Rating Scale and the Schedule for the Assessment of Negative Symptoms scale. Side effects were evaluated by means of the Simpson-Angus Scale for Extrapyramidal Symptoms, the Barnes Akathisia Scale and the Abnormal Involuntary Movement Scale. Multivariate analyses were employed to test possible influences of single nucleotide polymorphisms on clinical and safety variables. Analysis of haplotypes was also performed. No relevant association between FAT variants and clinical or safety scores was observed. Haplotype analysis did not reveal any significant association with clinical and safety scores at any time as well. Our data suggest no association between investigated alleles and genotypes in FAT and response to aripiprazole. However, because several limitations characterize the present study, further investigations on larger studies are required.

show abstract

Inter- and Intra-Rater Reliability of the Brief Psychiatric Rating Scale

Cited by 117 publications

References 8 publications

Negative impact of borderline global cognitive scores on quality of life after subthalamic nucleus stimulation in Parkinson's disease

Negative impact of borderline global cognitive scores on quality of life after subthalamic nucleus stimulation in Parkinson's disease

Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study

No influence of FAT polymorphisms in response to aripiprazole

Contact Info

Product

Resources

About